Marseille

• A Dose Escalation and Cohort Expansion Study of KB-0742 in Participants With Relapsed or Refractory Solid Tumors or Non-Hodgkin Lymphoma. Ended
  2023-503739-16-00 1 2023-12-20 Relapsed or refractory solid tumors or non-Hodgkin lymphoma
• Hidradenitis Suppurativa Phase 3 Study of Izokibep Ended
  2022-503160-33-00 5 2023-12-15 Hidradenitis Suppurativa
• Proof of concept treatment study of orally administered VH4004280 or VH4011499 in HIV-1 infected adults Ended
  2023-505350-18-00 4 2023-12-15 HIV Infections
• Study comparing radiotherapy combined with cetuximab + Xevinapant (study drug) with radiotherapy combined with cetuximab + placebo in patien … Ended
  2022-502584-38-00 5 2023-12-12 Locally advanced squamous cell carcinoma of the head and neck
• Phase 1/2 Study of BDC-1001 as a Single Agent and in Combination with Nivolumab in Patients with Advanced HER2-Expressing Solid Tumors Ended
  2024-518411-19-00 9 2023-12-04 Advanced HER2-Expressing Solid Tumors.
• Randomized, non-comparative, open-label early phase Ib study with OBT076 or OBT076 followed by Balstilimab in patients with Adenoid Cystic C … Ended
  2023-503270-20-00 3 2023-11-29 recurrent or metastatic Adenoid Cystic Carcinoma of the Head and Neck
• A Phase 2 Study Evaluating INCB099280 in Participants With Advanced Cutaneous Squamous Cell Carcinoma Ended
  2022-502476-23-00 4 2023-10-25 Treatment of immunotherapy-naive patients with previously untreated or
• A Study to Investigate MBS2320 Patients with IPF Ended
  2023-504418-30-00 4 2023-10-24 Idiopathic Pulmonary Fibrosis
• Detection of tumor DNA in the blood of patients receiving standard therapy for hormone receptorpositive (HR+) non-HER2 expressing (HER2-) me … Ended
  2022-502372-22-01 4 2023-10-19 Metastatic Breast Cancer HR+, HER2-
• A study to test whether spesolimab helps people with a skin disease called hidradenitis suppurativa Ended
  2022-501074-19-00 10 2023-10-13 Hidradenitis suppurativa
• A study to test the effect of Samuraciclib in Combination with Elacestrant in Participants with Hormone Receptor-positive (HR+) and Human Ep … Ended
  2023-503846-30-00 9 2023-10-10 Breast Cancer
• Phase II, multi‑cohort trial of neoadjuvant and post‑surgery IO102‑IO103 and pembrolizumab in patients with selected resectable tumors Ended
  2022-502787-20-00 4 2023-09-28 Melanoma and squamous cell carcinoma of the head and neck
• ELVN-002 in Solid Tumors with a HER2 Genetic Alteration Ended
  2022-502695-23-00 1 2023-09-27 Phase 1a Monotherapy Dose Escalation and Exploration: HER2 mutant, HE
• A Phase 1 Study of PRT3789 in Participants with Advanced or Metastatic Solid Tumors with a SMARCA4 Mutation Ended
  2022-502850-14-00 1 2023-09-25 gastroesophageal junction
• A Ph3 Study to Evaluate the Efficacy and Safety of Pegozafermin in Subjects with Severe Hypertriglyceridemia: The ENTRUST study Ended
  2023-503576-25-00 5 2023-09-22 Severe Hypertriglyceridemia
• A Phase 1 Study of BMS-986360/CC-90001 Alone and in Combination with Chemotherapy or Nivolumab in Advanced Solid Tumors Ended
  2022-500930-27-00 3 2023-09-15 Solid Tumor
• A study to learn how well a higher amount of aflibercept given as an injection into the eye works and how safe it is in people with reduced … Ended
  2022-502174-16-00 5 2023-09-13 Macular edema secondary to retinal vein occlusion
• A study to investigate response to ompenaclid combined with FOLFIRI plus bevacizumab in patients with advanced or metastatic colorectal canc … Ended
  2023-503356-27-00 4 2023-09-07 Metastatic colorectal cancer that is resistant to the currently approv
• A Study to Evaluate the Efficacy and Safety of Vixarelimab Compared with Placebo in Patients with Idiopathic Pulmonary Fibrosis and in Patie … Ended
  2022-502828-42-00 4 2023-09-01 Idiopathic Pulmonary Fibrosis
• A dose-escalation and expansion study of the safety and pharmacokinetics of XB002 as single-agent and combination therapy in subjects with i … Ended
  2023-508267-69-00 3 2023-08-11 Subjects with Aadvanced solid tumors for whom life-prolonging therapie
• Clinical trial of MK-7648A in adults and children with skin cancer Ended
  2022-501417-31-01 5 2023-08-01 melanoma
• A Study of TAK-676 as Single Agent and TAK-676 in Combination With Pembrolizumab in Adults With Advanced or Metastatic Solid Tumors Ended
  2023-505627-30-00 7 2023-07-26 Solid Neoplasm
• An 18-month study to assess joint outcomes in patients with haemophilia A or B on prophylaxis with efmoroctocog alfa or eftrenonacog alfa Ended
  2022-502921-16-00 6 2023-07-21 Hemophilia A and B
• DapaBalci-Leap Ended
  2024-516032-10-00 4 2023-07-13 Stage 3 chronic kidney disease

Showing 1,297–1,320 of 1,518 trials